Progenity to Showcase New Data at Digestive Disease Week®

Alongside their women’s health products, Progenity has an extensive and innovative pipeline of ingestible molecular diagnostics and therapeutic products in development for gastrointestinal disorders, such as inflammatory bowel disease and small intestinal bacterial overgrowth. Progenity will be presenting three posters at Digestive Disease Week^® 2019 held May 18-21 in San Diego, California:

Title: Development of a Swallowable Diagnostic Capsule to Monitor Gastrointestinal Health
Presenting Author: Mitchell Jones, M.D., Ph.D., Vice President, Translation and Clinical Development at Progenity
Session: Advanced Imaging of the Upper and Lower GI Tract
Date and Time: May 18, 2019; 12:00 PM – 2:00 PM PDT
Poster Number: Sa1717
Location: Poster Hall, San Diego Convention Center

Title: Development of Targeted Therapeutic Antibodies for the Treatment of Inflammatory Bowel Disease
Presenting Author: Mitchell Jones, M.D., Ph.D., Vice President, Translation and Clinical Development at Progenity
Session: IBD – Comparative Effectiveness Studies
Date and Time: May 19, 2019; 12:00 PM – 2:00 PM PDT
Poster Number: Su1875
Location: Poster Hall, San Diego Convention Center

Title: A Comparison Study of Systemic Versus Targeted Intracecal Anti-TNFα Monoclonal Antibody in an Adoptive T-cell Transfer Murine Model of Colitis
Author: Mitchell Jones, M.D., Ph.D., Vice President, Translation and Clinical Development at Progenity
Session: Animal Models – Preclinical Treatment of Intestinal Inflammation
Date and Time: May 19, 2019; 12:00 PM – 2:00 PM PDT
Poster Number: Su1809
Location: Poster Hall, San Diego Convention Center

More information about these studies will be made available on the Progenity website following the conference.

About DDW
Digestive Disease Week^® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 18-21, 2019, at the San Diego Convention Center. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.

About Progenity
Progenity, Inc., is a privately held biotechnology company with the mission of transforming healthcare to be more precise and personal. The company is translating innovation into precision medicine through diagnostic and therapeutic development platforms based on genomics/epigenomics, proteomics, and microbiomics. These platforms feed an R&D pipeline of innovative products designed to improve patient outcomes in prenatal and perinatal healthcare settings, oncology, and gastroenterology. Progenity’s ultimate vision is to make precision medicine a reality by both diagnosing disease at its source and treating it with targeted therapies developed by the company. Progenity is headquartered in San Diego, California. For more information on how Progenity is helping clinicians and patients prepare for life, please visit www.progenity.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190506005157/en/